AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cardio Diagnostics shares surge 17.44% premarket as CMS finalizes $854 Medicare payment rate for key tests.
ByAinvest
Wednesday, Dec 3, 2025 8:51 am ET1min read
Cardio Diagnostics Holdings surged 17.44% in premarket trading following the Centers for Medicare and Medicaid Services (CMS) announcement of a finalized $854 gapfill payment rate for its Epi+Gen CHD™ and PrecisionCHD™ tests. The rate, significantly higher than preliminary rates of $350 and $684.76, respectively, marks a key development in expanding access to the company’s AI-powered cardiovascular tests for Medicare beneficiaries. The CEO highlighted the importance of this approval for scaling operations, as the tests received dedicated CPT codes in April 2024. The final rate, effective January 1, 2026, removes regulatory uncertainty and signals strong future revenue potential, directly aligning with the stock’s sharp premarket rise.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet